Dr Yuhong Qiu has served as Vice President of Global Regulatory Affairs since May, 2018. Previously, Dr Qiu served as Executive Director of Regulatory Affairs at Novartis Oncology, where she worked for 12 years with increasing responsibilities. She has broad regulatory expertise spanning across both small and large molecule (biologics) development. Dr Qiu has led numerous successful global regulatory filings from first-to-human studies to marketing authorization applications. Before joining Novartis Oncology, Dr Qiu worked for 8 years at Johnson & Johnson, where she led a team of scientists in drug discovery and gained rich experience in drug candidate selection and characterization and preparation of nonclinical documents for first-in-human studies.
Dr Qiu received her Doctor of Philosophy degree and completed her postdoctoral training from the Baylor College of Medicine in Houston, Texas, USA. She received her Bachelor of Science degree in biochemistry from Wuhan University, China. Dr Qiu has authored or co-authored more than 30 publications in peer-reviewed journals.
Current role
Ilana Platt
VP, Innovation & Global Regulatory Affairs at CannTrust
Lynn Pawelski
VP, Global Regulatory Affairs at Baxter
Erik Berglund
VP, Global Regulatory Affairs at VistaGen Therapeutics
Rita Shah
VP, Global Regulatory Affairs at MBX Biosciences
Weicheng Wu
VP, Global Regulatory Affairs at ASC Therapeutics
Amy Smith
VP, Global Regulatory Affairs at MicroVention